Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Mirati Therapeutics, Inc. | mrtx-20171231xex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Mirati Therapeutics, Inc. | mrtx-20171231xex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Mirati Therapeutics, Inc. | mrtx-20171231xex311.htm |
| EX-21.1 - EXHIBIT 21.1 - Mirati Therapeutics, Inc. | exhibit211.htm |
| 10-K - 10-K - Mirati Therapeutics, Inc. | mrtx-20171231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statements (Form S-3 Nos. 333-198678, 333-206965, and 333-207848) of Mirati Therapeutics, Inc., |
(2) | Registration Statement (Form S-8 No. 333-218239) pertaining to the Amended and Restated 2013 Equity Incentive Plan of Mirati Therapeutics, Inc., |
(3) | Registration Statements (Form S-8 Nos. 333-196487, 333-204720) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics, Inc., and |
(4) | Registration Statement (Form S-8 No. 333-189965) pertaining to the Amended and Restated Incentive Stock Option Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan of Mirati Therapeutics Inc.; |
of our report dated March 8, 2018, with respect to the consolidated financial statements of Mirati Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mirati Therapeutics, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
San Diego, California
March 8, 2018